GlassScriptPhysician profile
Kamal P Singh
NPI 1902885759
$5,677.22
in general payments reported to CMS, 2019-2025
40 companies · $711 in 2025
The $711 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,088 · 2020: $776 · 2021: $790 · 2022: $885 · 2023: $740 · 2024: $688 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $926.11 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $642.24 | 2019-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $456.76 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Horizon Therapeutics Plc | $347.77 | 2019-2022 | |
| Glaxosmithkline, LLC. | $347.06 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $312.71 | 2021-2024 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $301.24 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $295.75 | 2019-2023 | Xarelto |
| Abbott Laboratories | $222.04 | 2021-2024 | Perclose Proglide, Mitraclip |
| Shield Therapeutics INC | $202.51 | 2023-2024 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.58 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $147.45 | 2019-2024 | Airsupra |
| Pfizer INC. | $142.57 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $120.34 | 2019-2022 | |
| Boston Scientific Corporation | $111.29 | 2025 | Farapulse, Baylis Medical Company Radiofrequency Puncture Generator |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.